BARCELONA — If a drug that clearly outperforms its control in a trial hits a home run, then the new oral anticoagulant dabigatran batted a grand slam against its comparator warfarin in a study that tested prevention of strokes and systemic embolism in patients with atrial fibrillation, according to several listeners.
PREVIEW